Cullen/Frost Bankers’s Viking Therapeutics VKTX Stock Holding History

Cullen/Frost Bankers’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-2	Closed	-$70	–	1561
2025 Q4	$70	Buy	+2	New	+$71	﹤0.01%	1432

Other funds holding VKTX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Raymond James Financial St Petersburg, Florida $324B AUM 22.36% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

American Century Companies Kansas City, Missouri $194B AUM 35% 1-Year Est. Return

Cullen/Frost Bankers's VKTX Position: Q1 2026 in Review

Cullen/Frost Bankers sold out of Viking Therapeutics (VKTX) in Q1 2026, closing a stake of 2 shares — an estimated $70 sold.

Cullen/Frost Bankers first reported a position in VKTX in Q4 2025 and held it in 1 quarter. The position peaked at $70 in Q4 2025. 410 funds tracked by Wall St. Rank hold VKTX as of Q1 2026.

Cullen/Frost Bankers reported no remaining Viking Therapeutics position as of Q1 2026 after selling out during the quarter.
Cullen/Frost Bankers sold 2 Viking Therapeutics shares in Q1 2026, an estimated $70.
Cullen/Frost Bankers first reported a position in Viking Therapeutics in Q4 2025 and held it in 1 quarter.
Cullen/Frost Bankers's Viking Therapeutics position peaked at $70 in Q4 2025.
410 funds tracked by Wall St. Rank held Viking Therapeutics as of Q1 2026.

Based on Cullen/Frost Bankers's 13F filing for Q1 2026, filed 5 May 2026.